论文部分内容阅读
目的:探讨孟鲁斯特钠联合异丙托溴铵治疗小儿支原体肺炎的临床疗效。方法:将2011年1月～2013年1月间来我院就诊的支原体肺炎患儿随机分为对照组51例和治疗组52例,对照组雾化吸入复方异丙妥溴胺1.5ml,2次/d;治疗组加用孟鲁斯特钠4mg/次,1次/d,10天为1疗程;疗程结束后对疗效进行评价,并记录患者症状体征的消除时间。结果:治疗组总有效率为88.5%,明显高于对照组的70.6%,且差异有统计学意义(x2=5.06,P<0.05);经治疗后治疗组咳嗽、喘息以及肺部啰音的消失时间明显少于对照组,且差异有统计学意义(P<0.05)。结论:孟鲁斯特钠联合复方异丙托溴铵治疗支原体肺炎患儿的疗效显著,可明显缩短患儿临床体征消失时间,值得临床推广。
Objective: To investigate the clinical efficacy of monastal sodium combined with ipratropium bromide in the treatment of mycoplasma pneumonia in children. Methods: Children with Mycoplasma pneumonia admitted to our hospital from January 2011 to January 2013 were randomly divided into control group (n = 51) and treatment group (n = 52). In the control group, Times / d; treatment group with sodium montelukast 4mg / time, 1 / d, 10 days for a course of treatment; after the end of the course of treatment to evaluate the efficacy and record of patients with symptoms and signs of elimination time. Results: The total effective rate in the treatment group was 88.5%, which was significantly higher than that in the control group (70.6%) (x2 = 5.06, P <0.05). After treatment, the cough, wheezing and pulmonary rales Disappear time was significantly less than the control group, and the difference was statistically significant (P <0.05). Conclusion: The combination of monastal sodium and compound ipratropium bromide in the treatment of children with mycoplasma pneumonia has significant curative effect, which can significantly shorten the disappearance time of clinical signs in children and deserve clinical promotion.